Fig. 5

In vivo immune activation and exertion of potent antitumor efficacy. (A) Schematic of the treatment protocol. Arrows indicate times of intravenous injection (TCuH NPs, n = 5). (B) Real-time bio-distribution images of ICuH NPs before and after injection. (C) In vivo infrared thermal imaging images of CT26 tumors in mice treated with TCuH NPs upon 1064 nm laser irradiation at 8 h after injection. (D) Tumor growth assessment and (E) photographs of excised tumor tissues. (F) H&E, TUNEL, Ki67, hypoxia, HIF-1a, HSP70, HSP90, and FDX1 staining in tumor sections from PBS, TPZ, TCu, TCuH, and TCuH + 1064 nm laser groups. Data are presented as means with standard deviations (n = 5)